Compare Coupang Inc (CPNG) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs Crispr Therapeutics AG — how do they compare? Coupang Inc trades at $16.37 (market cap $29.66B), while Crispr Therapeutics AG trades at $54 (market cap $5.23B). The key difference: Coupang Inc is far larger — about 5.7× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals.
| CPNG | CRSP | |
|---|---|---|
Market Cap | $29.66B | $5.23B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.53 | $76.78 |
52-Week Low | $15.12 | $44.34 |
Enterprise Value | $29.18B | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coupang (CPNG) trades at $16.42, up 1.42% on the day, with technical indicators showing a neutral to bearish bias as the stock consolidates near key support levels. The company reported mixed Q2 2026 results with revenue acceleration but missed earnings expectations, while maintaining strong revenue growth trends and positive operating cash flow of $1.77 billion in 2025. Recent news highlights Coupang's debut on the Fortune Global 500 and ongoing recovery from a data breach incident.
Despite near-term earnings pressure and regulatory challenges, Coupang maintains dominant market position in South Korean e-commerce with expanding Taiwan operations. Wall Street remains overwhelmingly bullish with 87.5% buy ratings and a $23.38 consensus price target representing 42% upside potential, though investors should monitor execution on profitability targets and resolution of the $422 million regulatory fine.
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
